CUE Cue Biopharma Inc

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the on February 25, 2021.

Presentation Details

Title: Next Generation Synthetic Vaccines

Immuno-STATs: Drugging the Tumor-specific T-cell Repertoire

Date and Time: Thursday, February 25, 2021 at 10:45 a.m. EST

Dr. Suri will present an overview of the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and its next generation derivative, Neo-STAT™. He will also highlight the IL-2 based CUE-100 series Immuno-STATs exemplified by CUE-101, the Company’s lead clinical candidate for HPV+ R/M HNSCC and CUE-102, our second drug program designed to target Wilms’ tumor 1 (WT1) specific T cells for the treatment of patients with solid and hematological cancers. The overview will include data supporting mechanistic advantages of the Immuno-STAT and Neo-STAT approach to targeting and activating disease-relevant T cells directly in the patient’s body.

Panel Details

Title: Vaccine Expert Discussion

Date and Time: Thursday, February 25, 2021 at 11:30 a.m. EST

About Immuno-STAT

The company’s Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologics are designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drugs is designed using our proprietary scaffold comprising: 1) a pMHC to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.

The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drug candidates are delivered directly in the patient’s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients’ T cells to be extracted, modified outside the body (ex vivo), and reinfused.

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit  and follow us on Twitter .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the potential of the CUE 100 series for anti-tumor activity; the potential benefits of the company’s Immuno-STAT™ platform biologics; the anticipated results of the company’s drug development efforts, including study results; the company’s expectations regarding regulatory developments and expected future operating results; and statements regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s limited operating history, limited cash and history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company’s operations and clinical trials; negative or inconclusive results from the company’s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact

George B. Zavoico, Ph.D.

VP, Investor Relations & Corporate Development

Cue Biopharma, Inc.

Media Contact

Karen O’Shea, Ph.D.

LifeSci Communications

 



EN
22/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cue Biopharma Inc

 PRESS RELEASE

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 20...

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company’s lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating i...

 PRESS RELEASE

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annu...

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024. During the presentation, Cue Biopharma’s chief executive officer, Dan Passeri, will provide a corporate update highlighting the late...

 PRESS RELEASE

Cue Biopharma to Present at the JMP Securities Hematology and Oncology...

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023. During the fireside chat, Cue Biopharma will discuss recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based C...

 PRESS RELEASE

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent ...

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023. Recent Business Highlights Presented positive data from ongoing Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC 2023) held November 1-5. Updated Phase 1 da...

 PRESS RELEASE

Cue Biopharma to Present at Three Upcoming Investor Healthcare Confere...

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London Healthcare Conference, to be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference, to be held in...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch